NCT05523804

Patient Outcomes Following Interval and Delayed Cytoreductive Surgery in Advanced Ovarian Cancer

Patient Outcomes Following Interval and Delayed Cytoreductive Surgery in Advanced Ovarian Cancer: A GO SOAR Led Study (GO SOAR2)

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 800 (estimated)
• Sponsor: NHS Grampian · Other Government
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To compare patient outcomes following interval and delayed cytoreductive surgeries and no surgery (neoadjuvant chemotherapy alone) and international variations in access to cytoreductive surgeries in women with advanced stage ovarian cancer.

Detailed description

Standard of care in patients with advanced ovarian cancer is primary cytoreductive surgery followed by chemotherapy. Neoadjuvant chemotherapy and interval cytoreductive surgery is an alternative in selected patients. Most data exist with interval cytoreductive surgery following 3-4 cycles of chemotherapy, however, some patients experience a delay. So far, the impact of delayed cytoreductive surgery (following \>5 cycles of chemotherapy) on patient outcomes is poorly defined. There is also a paucity of data in women who undergo no surgery (\>5 cycles of chemotherapy alone) and factors influencing international discrepancies in access to cytoreductive surgery.

Conditions

• Ovarian Cancer

Interventions

Type	Name	Description
PROCEDURE	interval cytoreductive surgery	cytoreductive surgery after 3-4 cycles of chemotherapy
PROCEDURE	delayed cytoreductive surgery	surgery after \>5 cycles of chemotherapy
OTHER	no surgery	no cytoreductive surgery (\>5 cycles of chemotherapy alone)

Timeline

• Start date: 2022-08-26
• Primary completion: 2023-12-31
• Completion: 2024-12-31
• First posted: 2022-08-31
• Last updated: 2022-08-31

Locations

1 site across 1 country: United Kingdom